Treatment of multiple sclerosis with interferon β: An appraisal of cost-effectiveness and quality of life

Journal of Neurology Neurosurgery and Psychiatry

Volumn 68, Issue 2, 2000, Pages 144-149

  Parkin, David ^a   Jacoby, Ann ^b   McNamee, Paul ^a   Miller, Paul ^b   Thomas, Simon ^b   Bates, David ^b  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

^b UNIVERSITY OF NOTTINGHAM   (United Kingdom)

Author keywords

Costs; Interferon ; Multiple sclerosis; Quality of life

Indexed keywords

BETA INTERFERON;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; COST EFFECTIVENESS ANALYSIS; DISABILITY; DISEASE COURSE; DRUG COST; DRUG EFFICACY; FEMALE; HEALTH STATUS; HUMAN; INJURY SCALE; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; PRIORITY JOURNAL; QUALITY OF LIFE; RECURRENT DISEASE; REMISSION; TREATMENT OUTCOME; UNITED KINGDOM;

ADJUVANTS, IMMUNOLOGIC; ADULT; AGED; CATCHMENT AREA (HEALTH); COST-BENEFIT ANALYSIS; FEMALE; GREAT BRITAIN; HEALTH CARE COSTS; HEALTH STATUS; HUMANS; INTERFERON-BETA; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; QUALITY OF LIFE; QUALITY-ADJUSTED LIFE YEARS; RECURRENCE; SEVERITY OF ILLNESS INDEX;

EID: 0034017018     PISSN: 00223050     EISSN: None     Source Type: Journal    
DOI: 10.1136/jnnp.68.2.144     Document Type: Article

References (23)

1. The IFNB Multiple Sclerosis Study Group. Interferon β-1b is effective in relapsing-remitting multiple sclerosis: I clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 1993;-43:655-61.
2. The IFNB Multiple Sclerosis Study Group and University of British Columbia MS/MRI Analysis Group. Interferon β-1b in the treatment of multiple sclerosis: final outcome of the randomised controlled trial. Neurology 1995;45:1277-85.
3. Jacobs LD, Cookfair DL, Rudick RA, et al. Intramuscular interferon β-1a for disease progression in relapsing multiple sclerosis. Ann Neurol 1996;39:285-93.
4. PRISMS Study Group. Randomised double-blind placebo-controlled study of Interferon β-1a in relapsing/remitting MS. Lancet 1998;352:1498-504.
5. European Study Group on Interferon β-1b in Secondary Progressive MS. Placebo-controlled multicentre randomised trial of interferon β-1b in treatment of secondary progressive MS. Lancet 1998;352:1491-7.
6. Parkin D, McNamee P, Jacoby A, et al. A cost-utility analysis of Interferon β for multiple sclerosis. Health Technology Assessment 1998;2:1-58.
7. Williams A. The role of the EUROQOL instrument in QALY calculations. York: University of York, Centre for Health Economics, 1995. (Discussion Paper 130.)
8. Dolan P, Gudex C, Kind P, et al. A social tariff for EuroQoL: results from a UK general population survey. York: University of York: Centre for Health Economics, 1995.
9. Kurtzke JF. Rating neurological impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983;33:1444-52.
10. Vickrey BG, Hays RD, Harooni R, et al. A health-related quality of life measure for multiple sclerosis. Qual Life Res 1995;4:187-206.
11. Ware JE, Sherbourne CD. A 36-item short-form health survey (SF-36) I. Conceptual framework and item selection. Med Care 1992;30:473-83.
12. Ware JE, Harris WJ, Gandell B, et al. MAP-R for windows: multitrait/multi-item analysis program - revised. Lincoln, USA: Quality Metric, 1998.
13. Drummond MF, O'Brien B, Stoddart GL, et al. Methods for the economic evaluation of health care programmes. Oxford: Oxford University Press, 1997.
14. Weinshenker BG, Bass B, Rice GPA, et al. The natural history of multiple sclerosis: a geographically based study. i. Clinical course and disability. Brain 1989;112:133-46.
15. Weinshenker BG, Bass B, Rice GPA, et al. The natural history of multiple sclerosis: a geographically based study. ii. Predictive value of the early clinical course. Brain 1989;112:1419-28.
16. Weinshenker BG, Rice GPA, Noseworthy JH, et al. The natural history of multiple sclerosis: a geographically based study. iii. Multivariate analysis of predictive factors and models of outcome. Brain 1991;114:1045-56.
17. Weinshenker BG, Rice GPA, Noseworthy JH, et al. The natural history of multiple sclerosis: a geographically based study. iv. Applications to planning and interpretations of clinical therapeutic trials. Brain 1991;114:1057-67.
18. Chartered Institute of Public Finance and Accountancy. Health service financial database. London: Health Service Management Association, 1996.
19. British Medical Association, Royal Pharmacological Society of Great Britain. British national formulary. London: BMA, RPSGB, 1996.
20. Netten A, Dennett J. Unit costs of health and social care. Canterbury: University of Kent at Canterbury: Personal Social Services Research Unit, 1996.
21. Jenkinson C, Coulter A, Wright L. Short-form 36 (SF-36) health survey questionnaire: normative data for adults of working age. BMJ 1993;306:1437-40.
22. Williams A. The measurement and valuation of health: a chronicle. York: University of York: Centre for Health Economics, 1995.
23. Canadian Coordinating Office for Health Technology Assessment. Interferon β-1b and multiple sclerosis. Ottawa: CCOHTA Technology Overview, 1996.